The MTM approach allows bone and mucogingival tissue to be regenerated without using exogenous materials. A substantial clinical and biological difference for complex cases.
Bone regeneration in implantology is traditionally associated with the use of barrier membranes, particulate bone substitutes and, in some cases, growth factors. Morphogenic Tissue Management (MTM) represents an alternative approach, developed in Rome by Dr. Gaetano Calesini together with Dr. Agostino Scipioni from the 1990s onwards, which achieves tissue regeneration without introducing exogenous materials into the operative site.
The biological principle
The term “morphogenic” derives from the Greek morphe (form) and genesis (origin). In this context, it refers to the induction of tissue morphogenesis activated by the controlled displacement of the osteo-muco-periosteal tissues during implant placement.
The founding concept of MTM is that the treated tissues already possess the biological resources necessary for regeneration: the multipotent stem cells present in the osteo-muco-periosteal complex, activated by the surgical procedure under appropriate conditions, produce bone and mucogingival regeneration without the need to introduce scaffolding materials, membranes or artificial bone substitutes.
How it differs from conventional protocols
Conventional guided bone regeneration (GBR) involves the use of barrier membranes positioned over the bone defect to exclude the ingrowth of epithelial cells and favour the colonisation of the clot by osteogenic cells. This is often combined with filling of the defect with autologous, heterologous or synthetic bone substitutes.
The MTM approach uses neither membranes nor filling materials. The operative principle is different: the surgical techniques specific to MTM create the environmental conditions (space, vascularisation, stability) for the tissues to regenerate autonomously, exploiting the biology of the osteo-muco-periosteal complex.
Clinical advantages of eliminating exogenous materials
The elimination of exogenous materials is not merely a philosophical choice: it has measurable clinical consequences.
- No risk of rejection or foreign body reaction.
- Significant reduction in the risk of infection at the operative site.
- Quality of the regenerated tissue: the bone that forms is the patient’s own native bone, not a substitute requiring long maturation times.
- Reduced post-operative morbidity compared to autologous bone harvesting procedures.
- Elimination of material costs, which in some conventional protocols are considerable.
- Dramatic reduction in total treatment time.
- A single surgical phase compared to the three (absent complications) required with membrane use.
Documentation and clinical dissemination
The MTM approach is documented by publications in indexed international journals and by a monograph published by Quintessenza Internazionale. It is taught in postgraduate master programmes and post-degree training programmes, and is currently used by clinicians who have followed the specific training developed by its originators.
For a deeper exploration of the MTM protocol, the scientific documentation and published clinical cases are available at implantologia-biomimetica.com.
Clinical indications
MTM is used in cases where a bone or mucogingival regenerative phase is required as part of an implant treatment pathway. Indications include peri-implant bone defects, post-extraction sites with significant bone loss, and implant retreatment situations where the residual site requires regeneration prior to re-placement.
The assessment of the indication is case-specific and is carried out on the basis of complete clinical and radiographic documentation, within the sequential planning approach that characterises Studio Calesini.